0000950170-24-034264.txt : 20240320 0000950170-24-034264.hdr.sgml : 20240320 20240320170904 ACCESSION NUMBER: 0000950170-24-034264 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240318 FILED AS OF DATE: 20240320 DATE AS OF CHANGE: 20240320 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Maduck Sean CENTRAL INDEX KEY: 0001698310 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 24768522 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0508 4 2024-03-18 0001088856 CORCEPT THERAPEUTICS INC CORT 0001698310 Maduck Sean C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 false true false false See Remarks true Common Stock 2024-03-18 4 M false 17219 3.88 A 92441 D Common Stock 2024-03-18 4 S false 17219 25.00 D 75222 D Common Stock 2024-03-19 4 M false 10000 2.61 A 85222 D Common Stock 10000 I See Footnote Common Stock 10000 I See Footnote Stock option (right to buy) 3.88 2024-03-18 4 M false 17219 0.00 D 2026-02-26 Common Stock 17219 117939 D Stock option (right to buy) 2.61 2024-03-19 4 M false 10000 0.00 D 2024-08-07 Common Stock 10000 0 D Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Fully exercisable. President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission. /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck 2024-03-20